Abstract
Objectives: The purpose of this study was to retrospectively validate the prognostic value of revised 2018 FIGO stage IIIC Methods: This is a retrospective analysis of patients with cervical cancer in stage III of the revised 2018 FIGO Staging System who received standardized treatment from 2011 to 2014 at a cancer hospital. Multi-group comparisons were performed with the Kruskal-Wallis H test and chi-square test. Survival curves were calculated using the Kaplan-Meier method and the log-rank test. A Cox proportional hazard regression model was used for multivariable analysis. Results: A total of 418 women were included, 42(10.0%) stage IIIA, 120(28.7%) stage IIIB, 190(45.5%) stage IIIC1 and 66(15.8%) stage IIIC2, there was no significant difference in histological type, tumor differentiation, tumor size, type of radiotherapy, consolidation chemotherapy among the four groups (all, P > 0.05). The stage IIIC1 patients were younger compared to those with stage IIIA (P 2 MPLNs had worse OS compared with those having Conclusions: Patients with stage IIIC1 represent a heterogeneous population with a variable prognosis, using T stage and a cut-off value of 2 MPLNs could gain a better predict prognostic outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
